GLPwatch
Papers (10401)
Page 46 of 174, ranked by citation count.
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas.
- Pharmacological Support for the Treatment of Obesity-Present and Future.
- Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats.
- Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study.
- Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents.
- Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets.
- Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
- Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD.
- <sup>68</sup>Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism.
- Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
- Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
- Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
- Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
- Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
- Skp2 is required for incretin hormone-mediated β-cell proliferation.
- Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.
- A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.
- Protection of exenatide for retinal ganglion cells with different glucose concentrations.
- Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.
- Liraglutide protects against lethal renal ischemia-reperfusion injury by inhibiting high-mobility group box 1 nuclear-cytoplasmic translocation and release.
- Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.
- Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells.
- Pharmacological management of obesity in pediatric patients.
- GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice.
- Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.
- Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.
- Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.
- Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.
- The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
- Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective.
- Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
- Long-term effectiveness and safety of liraglutide in clinical practice.
- Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
- The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
- Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells.
- Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway.
- Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
- Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care.
- Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
- Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.
- Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.
- The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study.
- The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
- Liraglutide-associated acute pancreatitis.
- Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice.
- Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.
- Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide.
- Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
- Pancreatitis: a potential complication of liraglutide?
- Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
- Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
- Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
- The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
- An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
- Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
- Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity.
- Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.